Welcome to our dedicated page for Indivior Pharmaceuticals SEC filings (Ticker: INDV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Indivior Pharmaceuticals, Inc. filings document formal disclosures for a Nasdaq-listed specialty pharmaceutical company focused on buprenorphine-based treatments for opioid use disorder. Its 8-K reports cover operating results, Regulation FD presentations, material agreements, capital-structure matters, and financing events, including the 0.625% Convertible Senior Notes due 2031.
Indivior’s proxy materials describe shareholder voting matters, board and governance practices, executive compensation, and the company’s operating roadmap for SUBLOCADE growth. The filing record also includes common-stock registration details, financial disclosures tied to its OUD treatment business, share-repurchase activity, and registration-status matters.
Indivior plc director David E. Wheadon has filed an initial Form 3 disclosing his ownership in the company. As of 01/01/2026, he beneficially owns 12,624 Ordinary Shares of Indivior plc, held directly. The filing lists no derivative securities such as options or warrants. The form is filed by a single reporting person, and the signature block references a Power of Attorney authorizing the signing of the report.
Indivior PLC’s chief financial officer Ryan Preblick has filed an initial Form 3 disclosing his equity holdings in the company. He beneficially owns 280,582 ordinary shares directly. In addition, he holds restricted stock units that each represent a contingent right to receive one ordinary share of Indivior PLC.
One grant covers 6,302 restricted stock units that were awarded on March 14, 2024 and vest in a single installment on March 14, 2026. A second grant covers 70,459 restricted stock units that were awarded on March 7, 2025 and vest in a single installment on March 7, 2028. All positions are reported as directly owned, and the filing also includes a power of attorney authorizing the signatory to sign on his behalf.
Indivior plc director Keith Humphreys filed an initial statement of beneficial ownership, reporting that he directly owns 5,027 Ordinary Shares of Indivior plc as of 01/01/2026. The filing shows only non-derivative holdings, with no derivative securities such as options or warrants listed in the derivative securities table.
Indivior PLC's Chief Scientific Officer, Christian Heidbreder, reports his current equity holdings in the company. Heidbreder beneficially owns 157,140 ordinary shares on a direct basis.
He also holds 82,287 restricted stock units, each representing a contingent right to receive one ordinary share of Indivior PLC. These RSUs were granted on March 7, 2025 and vest in a single installment on March 7, 2028.
Indivior PLC reported the initial holdings of its Chief Legal Officer, Jeffrey W. Burris, in a Form 3 insider filing. He directly beneficially owns 760 ordinary shares of Indivior PLC. He also holds 71,743 restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. These RSUs were granted on March 7, 2025 and are scheduled to vest in a single installment on March 7, 2028, aligning his long-term compensation with the company’s future performance.
Indivior PLC executive Barry Patrick A, Chief Commercial Officer, filed an initial ownership report showing beneficial ownership of 130,312 restricted stock units. Each RSU represents a contingent right to receive one ordinary share of Indivior PLC. The RSUs were granted on June 2, 2025 and are scheduled to vest in a single installment on June 2, 2028, subject to applicable conditions. The filing is a Form 3, reflecting his derivative equity holdings as of the January 1, 2026 event date and does not report any purchase or sale transaction.
Indivior PLC’s Chief Accounting Officer, Anderson Woodrow D, has reported his initial beneficial ownership of the company’s securities as of 01/01/2026. He directly holds 4,390 ordinary shares.
He also holds several batches of restricted stock units (RSUs), each representing a right to receive one ordinary share of Indivior PLC. These include 5,946 RSUs granted on March 3, 2023 that vest in a single installment on March 3, 2026, 5,093 RSUs granted on March 8, 2024 that vest on March 8, 2027, and 29,478 RSUs granted on March 7, 2025 that vest on March 7, 2028. All positions are reported as directly owned.
Indivior PLC reported changes to executive compensation. On December 12, 2025, the Board of Directors approved base salary increases for two executive officers, effective January 1, 2026. The Chief Executive Officer, Joseph Ciaffoni, will have his annual base salary increased from $1,050,000 to $1,115,000. The Chief Financial Officer, Ryan Preblick, will have his annual base salary increased from $559,000 to $604,000. The Board made these changes after reviewing competitive market data and considering recommendations from the Compensation Committee and its compensation consultant.
Indivior PLC obtained strong shareholder approval for a scheme of arrangement and amended and restated articles of association that reshape its corporate structure. A new Article 136 ensures that any ordinary shares issued after the Amended Articles take effect but before the Scheme Record Time are automatically subject to the scheme, so all Indivior PLC shareholders will become shareholders of Indivior Pharmaceuticals, Inc. and Indivior PLC will become its wholly-owned subsidiary.
At a Court Meeting, 15 shareholders voted for the scheme and 2 against, with 94,968,161 votes for and 46,544 against, exceeding the English law requirement of a majority in number representing not less than seventy-five percent in value of shares present and voting. At an Extraordinary General Meeting, shareholders passed six related special resolutions, including authorising directors to implement the scheme, reducing share capital, issuing New Indivior Shares, amending articles, re-registering the company as a private company limited by shares, and adopting post-scheme articles. Completion of the scheme still depends on sanction by the High Court of Justice, with a hearing expected on January 22, 2026, and completion is expected later in January 2026.
Indivior PLC reported that it has fulfilled all remaining obligations under its Resolution Agreement with the U.S. Department of Justice and the U.S. Attorney’s Office for the Western District of Virginia. After these obligations were satisfied, the Resolution Agreement terminated on November 20, 2025. The company also issued a press release on the same date announcing payment of the remaining amounts owed to the DOJ, which is included as an exhibit to this report. This marks the formal conclusion of that material agreement with U.S. authorities.